RenovoRx and Imugene Announce Collaboration
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
Source: briefingwire.com
📰 Life Sciences Edition News
Life Sciences Edition News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Life Sciences Edition. Real-time updates on events, politics, business and more.
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
 Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platformTAMP enables localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver
Source: prwire.com.au
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform
Source: newsmaker.com.au
Imugene will collaborate with RenovoRx to deliver oncolytic virus through proprietary TAMP platform
Immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF) has entered into a strategic research collaboration with clinical-stage biopharmaceutical RenovoRx,...
Source: proactiveinvestors.com
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMPâ„¢) Platform
Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform.TAMP enables localized, targeted delivery of CF33 to...
Source: marketscreener.com
Business.Scoop » RenovoRx And Imugene Announce Collaboration To Deliver Oncolytic Virus Therapy Using Proprietary TAMP Platform
Business Scoop provides news and views on Business and Markets from New Zealand
New South Wales Leslie Chong Shaun Bagai Renovorx Inc Drug Delivery Technology Life Sciences Edition
Source: scoop.co.nz
RenovoRx And Imugene Announce Collaboration To Deliver Oncolytic Virus Therapy Using Proprietary TAMP Platform
Collaboration will explore trans-arterial delivery of Imugene's CF33 oncolytic virus utilizing RenovoRx's TAMP therapy platform TAMP enables localized, targeted delivery of CF33 to difficult-to-access tumors, such as pancreatic and liver tumors. Los Altos, ...
Source: scoop.co.nz
Signatera™ Wins Fierce Life Sciences Innovation Award
/PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that its personalized molecular residual...
Source: prnewswire.com